Cosmos Health Inc. income statement
In fiscal 2025, Cosmos Health Inc. reported revenue of $65.3m, up 19.9% on the year before, operating income of −$16.7m (a -25.6% margin) and net income of −$19.1m, or −$0.63 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 8 | 1 | 7 | 30 | 37 | 40 | 55 | 56 | 50 | 53 | 54 | 65 | 74 |
| Cost of revenue | — | — | 0 | 6 | 28 | 35 | 36 | 47 | 48 | 44 | 49 | 50 | 57 | 66 |
| Gross profit | — | 8 | 0 | 1 | 2 | 2 | 4 | 8 | 8 | 6 | 4 | 4 | 8 | 8 |
| Research and development | — | — | — | — | — | — | — | — | — | — | 0 | 1 | 1 | 0 |
| Selling and marketing | — | — | — | — | — | — | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| General and administrative | 0 | 0 | 0 | 1 | 5 | 4 | 3 | 2 | 9 | 10 | 20 | 12 | 16 | 17 |
| Operating income | 0 | 7 | −0 | −0 | −5 | −1 | −0 | 3 | −5 | −7 | −22 | −16 | −17 | −18 |
| Interest expense | — | 0 | 0 | 0 | 1 | −1 | −1 | 3 | 3 | 2 | 1 | 1 | 2 | 2 |
| Net interest income | — | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Non-interest expense | — | — | — | 0 | 1 | −6 | 0 | 0 | — | 0 | — | — | — | — |
| Income before tax | 0 | 7 | −7 | −1 | −6 | −9 | −3 | 1 | −8 | −13 | −19 | −16 | −19 | −24 |
| Income tax | 0 | 1 | 0 | 0 | 0 | −0 | 0 | −0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Net income | 0 | 6 | −7 | −1 | −6 | −9 | −3 | 1 | −8 | −14 | −19 | −16 | −19 | −24 |
| Diluted EPS | $0.00 | $0.33 | −$0.33 | $538273.33 | −$3.27 | −$4.53 | −$1.67 | $0.40 | −$7.91 | −$33.16 | −$2.15 | −$1.17 | −$0.63 | −$0.56 |
| Diluted shares (average) | 2m | 2m | 2m | 2m | 2m | 2m | 2m | 2m | 2m | 2m | 12m | 19m | 30m | 43m |
| EBITDA | — | 7 | −0 | −0 | −5 | −1 | 0 | 3 | −4 | −7 | −21 | −14 | −15 | −17 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 14 | 14 | 15 | 17 | 20 | 18 | 19 |
| Cost of revenue | 11 | 13 | 12 | 14 | 15 | 18 | 17 | 17 |
| Gross profit | 1 | 1 | 2 | 1 | 3 | 2 | 1 | 2 |
| Research and development | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General and administrative | 2 | 7 | 1 | 1 | 2 | 11 | 2 | 2 |
| Operating income | −2 | −9 | −1 | −3 | −2 | −11 | −2 | −3 |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Income before tax | −2 | −10 | −1 | −3 | −5 | −10 | −3 | −6 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −8 | −3 | −1 | −3 | −5 | −10 | −3 | −6 |
| Diluted EPS | −$0.45 | −$0.45 | −$0.03 | −$0.10 | −$0.17 | −$0.31 | −$0.06 | −$0.10 |
| EBITDA | −2 | −9 | −1 | −2 | −1 | −11 | −2 | −3 |
Compare with peers
- Cellyan Biotechnology Co., Ltd income statement
- 111, Inc. income statement
- Henry Schein income statement
- Cencora income statement
- McKesson income statement
Head to head: COSM vs HKPDCOSM vs YICOSM vs HSIC
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies